Portal de Periódicos da CAPES

Vitamin D and Prostate Cancer

2002; Wiley; Volume: 23; Issue: 1 Linguagem: Inglês

10.1002/j.1939-4640.2002.tb02596.x

2047-2927

Tara C. Polek, Nancy L. Weigel,

Cancer-related Molecular Pathways

Journal of AndrologyVolume 23, Issue 1 p. 9-17 Free Access Vitamin D and Prostate Cancer TARA C. POLEK, TARA C. POLEK From the Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.Search for more papers by this authorNANCY L. WEIGEL PhD, Corresponding Author NANCY L. WEIGEL PhD [email protected] From the Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas. Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030.Search for more papers by this author TARA C. POLEK, TARA C. POLEK From the Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.Search for more papers by this authorNANCY L. WEIGEL PhD, Corresponding Author NANCY L. WEIGEL PhD [email protected] From the Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas. Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030.Search for more papers by this author First published: 02 January 2013 https://doi.org/10.1002/j.1939-4640.2002.tb02596.xCitations: 50AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., Yoshiki S., Suda T. Differentiation of mouse myeloid leukemia cells induced by 1 alpha, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA. 1981; 78: 4990– 4994. Ahonen MH, Tenkanen L., Teppo L., Hakama M., Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 2000; 11: 847– 852. Barreto AM, Schwartz GG, Woodruff R., Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev. 2000; 9: 265– 270. Bar-Shavit Z., Teitelbaum SL, Reitsma P., Hall A., Pegg LE, Trial J., Kahn AJ. Induction of monocytic differentiation and bone resorption by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA. 1983; 80: 5907– 5911. Blazer DG III, Umbach DM, Bostick RM, Taylor JA. Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinog. 2000; 27: 18– 23. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997; 138: 1491– 1497. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology. 2000a; 141: 10– 17. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000b; 60: 779– 782. Blutt SE, Weigel NL. Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999; 221: 89– 98. Boehm MF, Fitzgerald P., Zou A., Elgort MG, Bischoff ED, Mere L., Mais DE, Bissonnette RP, et al. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem Biol. 1999; 6: 265– 275. Bookstein R., Shew JY, Chen PL, Scully P., Lee WH. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science. 1990; 247: 712– 715. Bouillon R., Verstuyf A., Verlinden L., Allewaert K., Branisteanu D., Mathieu C., Van Baelen H. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol. 1995; 50: 577– 583. Boyle BJ, Zhao XY, Cohen P., Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha, 25-dihydroxyvitamin D3 growth inhibition in the LNCaP prostate cancer cell line through p21/waf1. J Urol. 2001; 165: 1319– 1324. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control. 1995; 6: 235– 239. Brawn PN, Johnson EH, Kuhl DL, Riggs MW, Speights VO, Johnson CF 3rd, Pandya PP, Lind ML, Bell NF. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer. 1993; 71: 2569– 2573. Bromleigh VC, Freedman LP. p21 is a transcriptional target of HOXA10 in differentiating myelomonocytic cells. Genes Dev. 2000; 14: 2581– 2586. Brown AJ, Dusso A., Slatopolsky E. Vitamin D. Am J Physiol. 1999; 277: F157– F175. Campbell MJ, Elstner E., Holden S., Uskokovic M., Koeffler HP. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol. 1997; 19: 15– 27. Campbell MJ, Reddy GS, Koeffler HP. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem. 1997; 66: 413– 425. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998; 160: 2428– 2434. Chan JM, Stampfer MJ, Giovannucci E., Gann PH, Ma J., Wilkinson P., Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998; 279: 563– 566. Chapuy M., Meunier PJ. Vitamin D insufficiency in adults and the elderly. In: D. Feldman, FH Glorieux, JW Pike, eds. Vitamin D. San Diego, Calif: Academic Press; 1997: 679– 693. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982; 1: 74– 76. Colston KW, Berger U., Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet. 1989; 1: 188– 191. Colston KW, Mackay AG, James SY, Binderup L., Chander S., Coombes RC. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol. 1992; 44: 2273– 2280. Cook LS, Goldoft M., Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999; 161: 152– 155. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M., Vollmer RT, Lobaugh B., Drezner MK, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993; 2: 467– 472. Correa-Cerro L., Berthon P., Haussler J., Bochum S., Drelon E., Mangin P., Fournier G., Paiss T., et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet. 1999; 105: 281– 287. De Vos S., Holden S., Heber D., Elstner E., Binderup L., Uskokovic M., Rude B., Chen DL, et al. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate. 1997; 31: 77– 83. Denis LJ. Maximal androgen blockade: facts and fallacies. Endocr Rel Cancer. 1998; 5: 353– 356. Djulbegovic B., Christmas SE, Evans G., Moore M. Studies of the effect of 1,25-dihydroxycholecalciferol on the proliferation and differentiation of the human promyelocytic leukaemia cell line HL-60. Biomed Pharmacother. 1986; 40: 407– 416. Drivdahl RH, Loop SM, Andress DL, Ostenson RC. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate. 1995; 26: 72– 79. Eisman JA. Genetics of osteoporosis. Endocr Rev. 1999; 20: 788– 804. Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987; 47: 21– 25. Eisman JA, Koga M., Sutherland RL, Barkla DH, Tutton PJ. 1,25-Dihydroxyvitamin D3 and the regulation of human cancer cell replication. Proc Soc Exp Biol Med. 1989; 191: 221– 226. Esquenet M., Swinnen JV, Heyns W., Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1 alpha, 25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate. 1996; 28: 182– 194. Fife RS, Sledge GW Jr, Proctor C. Effects of vitamin D3 on proliferation of cancer cells in vitro. Cancer Lett. 1997; 120: 65– 69. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992; 3: 65– 71. Gann PH, Ma J., Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996; 5: 121– 126. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse mono-clonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31: 13– 20. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R., Shurin Z., et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1997; 50: 999– 1006. Gross C., Eccleshall TR, Malloy PJ, Villa ML, Marcus R., Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res. 1996a; 11: 1850– 1855. Gross C., Skowronski R., Plymate S., Rhim J., Peehl D., Feldman D. Simian virus 40-, but not human papillomavirus, transformation of prostatic epithelial cells results in loss of growth inhibition by 1,25 dihyroxy-vitamin D3. Int J Oncol. 1996b; 8: 41– 47. Gross C., Stamey T., Hancock S., Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) [erratum appears in J Urol. 1998; 160 (3 part 1):840]. J Urol. 1998; 159: 2035– 2039; discussion 2039–2040. Habuchi T., Suzuki T., Sasaki R., Wang L., Sato K., Satoh S., Akao T., Tsuchiya N., et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000; 60: 305– 308. Halloran BP, Portale AA. Vitamin D metabolism: the effects of aging. In: D. Feldman, FH Glorieux, JW Pike, eds. Vitamin D. San Diego, Calif: Academic Press; 1997: 541– 554. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 1992; 70: 2861– 2869. Hansen CM, Maenpaa PH. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem Pharmacol. 1997; 54: 1173– 1179. Hedlund TE, Moffatt KA, Miller GJ. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology. 1996a; 137: 1554– 1561. Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1 alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol. 1996b; 58: 277– 288. Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res. 1997; 3: 1331– 1338. Hisatake J., Kubota T., Hisatake Y., Uskokovic M., Tomoyasu S., Koeffler HP. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res. 1999; 59: 4023– 4029. Holick MF. The photobiology of vitamin D3 in man. In: R. Kumar, ed. Vitamin D: Basic and Clinical Aspects. Boston, Mass: Martinus Nijhoff; 1984: 197– 216. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980; 14: 29– 35. Horst RL, Reinhardt TA. Vitamin D metabolism. In: D. Feldman, FH Glorieux, JW Pike, eds. Vitamin D. San Diego, Calif: Academic Press; 1997: 13– 31. Hsieh T., Wu JM. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1 alpha, 25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun. 1997; 235: 539– 544. Hsieh TY, Ng CY, Mallouh C., Tazaki H., Wu JM. Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha, 25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun. 1996; 223: 141– 146. Huynh H., Pollak M., Zhang JC. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol. 1998; 13: 137– 143. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L., Wang W., Haile RW. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res. 1998; 58: 1620– 1623. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G., Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997; 89: 166– 170. Jones G., Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998; 78: 1193– 1231. Kaplan PJ, Mohan S., Cohen P., Foster BA, Greenberg NM. The insulinlike growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 1999; 59: 2203– 2209. Kibel AS, Isaacs SD, Isaacs WB, Bova GS. Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol. 1998; 160: 1405– 1409. Kissmeyer AM, Binderup E., Binderup L., Hansen C. Mork, Andersen NR, Makin HL, Schroeder NJ, Shankar VN, Jones G. Metabolism of the vitamin D analog EB1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol. 1997; 53: 1087– 1097. Koike M., Koshizuka K., Kawabata H., Yang R., Taub HE, Said J., Uskokovic M., Tsuruoka N., Koeffler HP. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Anticancer Res. 1999; 19: 1689– 1697. Konety BR, Lavelle JP, Pirtskalaishvili G., Dhir R., Meyers SA, Nguyen TS, Hershberger P., Shurin MR, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2001; 165: 253– 258. Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ. 1996; 7: 1563– 1570. Krill D., Stoner J., Konety BR, Becich MJ, Getzenberg RH. Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology. 1999; 54: 171– 177. Kubota T., Koshizuka K., Koike M., Uskokovic M., Miyoshi I., Koeffler HP. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res. 1998; 58: 3370– 3375. Leewansangtong S., Crawford ED. Maximal androgen withdrawal for prostate cancer therapy: current status and future potential. Endocr Rel Cancer. 1998; 5: 325– 339. Lissner D., Mason RS, Posen S. Stability of vitamin D metabolites in human blood serum and plasma. Clin Chem. 1981; 27: 773– 774. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev. 1999; 8: 241– 248. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer. 1999; 35: 1886– 1894. Ly LH, Zhao XY, Holloway L., Feldman D. Liarozole acts synergistically with 1 alpha, 25-dihydroxyvitamin D3 to inhibit growth of DU145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 1999; 140: 2071– 2076. Ma J., Stampfer MJ, Gann PH, Hough HL, Giovannucci E., Kelsey KT, Hennekens CH, Hunter DJ. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev. 1998; 7: 385– 390. MacDonald PN, Dowd DR, Nakajima S., Galligan MA, Reeder MC, Haussler CA, Ozato K., Haussler MR. Retinoid X receptors stimulate and 9-cis retinoic acid inhibits 1,25-dihydroxyvitamin D3-activated expression of the rat osteocalcin gene. Mol Cell Biol. 1993; 13: 5907– 5917. MacLaughlin J., Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985; 76: 1536– 1538. Majewski S., Skopinska M., Marczak M., Szmurlo A., Bollag W., Jablonska S. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Invest Dermatol Symp Proc. 1996; 1: 97– 101. Mangelsdorf DJ, Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83: 835– 839. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha, 25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res. 2000; 87: 214– 220. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S., Hedlund TE, Upadhya P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Res. 1992; 52: 515– 520. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1 alpha, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res. 1995; 1: 997– 1003. Moffatt KA, Johannes WU, Miller GJ. 1 alpha, 25-dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 1999; 5: 695– 703. Navone NM, Olive M., Ozen M., Davis R., Troncoso P., Tu SM, Johnston D., Pollack A., et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997; 3: 2493– 2500. Nemere I., Dormanen MC, Hammond MW, Okamura WH, Norman AW. Identification of a specific binding protein for 1 alpha, 25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem. 1994; 269: 23750– 23756. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994; 54: 805– 810. Qazi R., Khandekar J. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1983; 6: 203– 205. Russell PJ, Bennett S., Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem. 1998; 44: 705– 723. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology. 1995; 46: 365– 369. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990; 10: 1307– 1311. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res. 1994; 14: 1077– 1081. Schwartz GG, Wang MH, Zang M., Singh RK, Siegal GP. 1 alpha, 25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 1997; 6: 727– 732. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 1998; 7: 391– 395. Simboli-Campbell M., Narvaez CJ, Tenniswood M., Welsh J. 1,25-dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 1996; 58: 367– 376. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993; 132: 1952– 1960. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995; 136: 20– 26. Stattin P., Bylund A., Rinaldi S., Biessy C., Dechaud H., Stenman UH, Egevad L., Riboli E., et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000; 92: 1910– 1917. Studzinski GP, Bhandal AK, Brelvi ZS. Cell cycle sensitivity of HL-60 cells to the differentiation-inducing effects of 1 alpha, 25-dihydroxyvitamin D3. Cancer Res. 1985; 45: 3898– 3905. Sundaram S., Gewirtz DA. The vitamin D3 analog EB1089 enhances the response of human breast tumor cells to radiation. Radiat Res. 1999; 152: 479– 486. Sung V., Feldman D. 1,25-dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol. 2000; 164: 133– 143. Taylor JA, Hirvonen A., Watson M., Pittman G., Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996; 56: 4108– 4110. Thomas MG, Tebbutt S., Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut. 1992; 33: 1660– 1663. Trump DL, Marsh JC, Kvols LK, Citrin D., Davis TE, Hahn RG, Vogl SE. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs. 1990; 8: S91– S94. VanWeelden K., Flanagan L., Binderup L., Tenniswood M., Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology. 1998; 139: 2102– 2110. Wijngaarden T. Vink-van, Pols HA, Buurman CJ, Birkenhager JC, Van Leeuwen JP. Combined effects of 1,25-dihydroxyvitamin D3 and tamoxifen on the growth of MCF-7 and ZR-75–1 human breast cancer cells. Breast Cancer Res Treat. 1994; 29: 161– 168. Watanabe M., Fukutome K., Murata M., Uemura H., Kubota Y., Kawamura J., Yatani R. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res. 1999; 19: 4511– 4514. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol. 1994; 72: 537– 545. Wolk A., Mantzoros CS, Andersson SO, Bergstrom R., Signorello LB, Lagiou P., Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998; 90: 911– 915. Zhao XY, Ly LH, Peehl DM, Feldman D. 1 alpha, 25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology. 1997; 138: 3290– 3298. Zhao XY, Peehl DM, Navone NM, Feldman D. 1 alpha, 25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology. 2000; 141: 2548– 2556. Zhuang SH, Burnstein KL. Antiproliferative effect of 1 alpha, 25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998; 139: 1197– 1207. Citing Literature Volume23, Issue1January‐February 2002Pages 9-17 ReferencesRelatedInformation